Akums Drugs and Pharmaceuticals (NSE:AKUMS) Notes Receivable: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AKUMS Akums Drugs and Pharmaceuticals Ltd NSE:AKUMS
39 GF Score
Price ₹687.30
! 7 Warning Signs
View Full Analysis

What is Akums Drugs and Pharmaceuticals Notes Receivable?

Akums Drugs and Pharmaceuticals NSE:AKUMS -1.24% 39 Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:AKUMS with a GF Score™ of 39/100. The stock has 7 warning signs investors should review.

Akums Drugs and Pharmaceuticals's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0 Mil.

Akums Drugs and Pharmaceuticals Notes Receivable Related Terms

Akums Drugs and Pharmaceuticals Notes Receivable Historical Data

* Premium members only.

The historical data trend for Akums Drugs and Pharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akums Drugs and Pharmaceuticals Notes Receivable Chart

Akums Drugs and Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Akums Drugs and Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:AKUMS
39GF Score
Akums Drugs and Pharmaceuticals Ltd NSE:AKUMS
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akums Drugs and Pharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0 Mil mean?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a Notes Receivable of ₹0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Akums Drugs and Pharmaceuticals and its competitors.
Is Akums Drugs and Pharmaceuticals' Notes Receivable too high?
Akums Drugs and Pharmaceuticals' current Notes Receivable is ₹0 Mil. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' Notes Receivable compare to ZTS?
Akums Drugs and Pharmaceuticals' Notes Receivable of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Akums Drugs and Pharmaceuticals and its competitors. Akums Drugs and Pharmaceuticals's current Notes Receivable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current Notes Receivable of ₹0 Mil. The current Notes Receivable is ₹0 Mil. Akums Drugs and Pharmaceuticals' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akums Drugs and Pharmaceuticals Business Description

Other Exchanges 544222:India
Address Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
39GF Score

Get the complete analysis for NSE:AKUMS

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹687.30
Price